192 related articles for article (PubMed ID: 36517194)
1. Myths About Bladder Preservation in Muscle-Invasive Bladder Cancer.
Elumalai T; Joseph N; Choudhury A
Semin Radiat Oncol; 2023 Jan; 33(1):56-61. PubMed ID: 36517194
[TBL] [Abstract][Full Text] [Related]
2. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review.
Koga F; Kihara K
Int J Urol; 2012 May; 19(5):388-401. PubMed ID: 22409269
[TBL] [Abstract][Full Text] [Related]
3. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy.
Smith ZL; Christodouleas JP; Keefe SM; Malkowicz SB; Guzzo TJ
BJU Int; 2013 Jul; 112(1):13-25. PubMed ID: 23356411
[TBL] [Abstract][Full Text] [Related]
4. Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer.
Ballas L; Singh P; Lerner SP
Urol Oncol; 2023 Jan; 41(1):35-38. PubMed ID: 33153882
[TBL] [Abstract][Full Text] [Related]
5. The Role of Neoadjuvant Chemotherapy in Bladder Preservation Approaches in Muscle-Invasive Bladder Cancer.
Stecca C; Mitin T; Sridhar SS
Semin Radiat Oncol; 2023 Jan; 33(1):51-55. PubMed ID: 36517193
[TBL] [Abstract][Full Text] [Related]
6. Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.
Hensley PJ; Seiler R; Herr H; Mouw KW; Iyer G; Dyrskjøt L; Nawroth R; Goebell P; Schmitz-Drager B; Todenhofer T; Black PC; Kamat AM; Williams SB
Urol Oncol; 2023 Jul; 41(7):307-312. PubMed ID: 36702704
[TBL] [Abstract][Full Text] [Related]
7. Management of surgically inoperable muscle-invasive bladder cancer in a resource constraint setting at a tertiary care center by bladder preservation protocol: Case series.
Kumar A; Kumar M; Semwal MK; Singh U; Mishra N
J Cancer Res Ther; 2023; 19(3):725-730. PubMed ID: 37470601
[TBL] [Abstract][Full Text] [Related]
8. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
9. Trimodality bladder preservation therapy for muscle-invasive bladder cancer.
Chen RC; Shipley WU; Efstathiou JA; Zietman AL
J Natl Compr Canc Netw; 2013 Aug; 11(8):952-60. PubMed ID: 23946174
[TBL] [Abstract][Full Text] [Related]
10. How Small Can We Go? Partial Bladder Radiation Therapy and Brachytherapy.
Kahn JM; Smits GAHJ; Oosterveld BJ; van der Steen-Banasik EM
Semin Radiat Oncol; 2023 Jan; 33(1):76-81. PubMed ID: 36517197
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
[TBL] [Abstract][Full Text] [Related]
12. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
13. Bladder preservation in urothelial carcinoma: current trends and future directions.
Goodstein T; Wang SJ; Lee CT
Curr Opin Support Palliat Care; 2021 Dec; 15(4):253-259. PubMed ID: 34726191
[TBL] [Abstract][Full Text] [Related]
14. Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer.
Swinton M; Devi A; Song YP; Hoskin P; Choudhury A
World J Urol; 2024 Apr; 42(1):210. PubMed ID: 38573431
[TBL] [Abstract][Full Text] [Related]
15. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
16. The Legacy of RTOG/NRG Protocols in Shaping Current Bladder Preservation Therapy in North America.
Kamran SC; Efstathiou JA
Semin Radiat Oncol; 2023 Jan; 33(1):26-34. PubMed ID: 36517191
[TBL] [Abstract][Full Text] [Related]
17. Bladder sparing surgery in high-grade bladder cancer.
Yakovlev PG; Klyushin DA; Vereshchako RI
Exp Oncol; 2019 Jun; 41(2):160-165. PubMed ID: 31262149
[TBL] [Abstract][Full Text] [Related]
18. Bladder preservation strategy based on combined therapy in patients with muscle-invasive bladder cancer: management and results at long-term follow-up.
Villavicencio H; Rodriguez Faba O; Palou J; Gausa L; Algaba F; Marcuello E
Urol Int; 2010; 85(3):281-6. PubMed ID: 20689253
[TBL] [Abstract][Full Text] [Related]
19. Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer.
de Angelis M; Basile G; Scornajenghi CM; Asero V; Del Giudice F; Moschini M
Curr Opin Urol; 2023 Sep; 33(5):354-359. PubMed ID: 37395512
[TBL] [Abstract][Full Text] [Related]
20. Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers.
El-Taji OM; Alam S; Hussain SA
Curr Treat Options Oncol; 2016 Mar; 17(3):15. PubMed ID: 26942590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
